Intra-Cellular Therapies Inc’s recently made public that its Director ALEXANDRIA VENTURE INVESTMENTS acquired Company’s shares for reported $2.63 million on Mar 18 ’25. In the deal valued at $131.42 per share,20,000 shares were bought.
Then, ALEXANDRIA VENTURE INVESTMENTS bought 11,750 shares, generating $1,544,292 in total proceeds.
Before that, Mates Sharon sold 51,000 shares. Intra-Cellular Therapies Inc shares valued at $4,375,659 were divested by the Chairman and CEO at a price of $85.80 per share. As a result of the transaction, Mates Sharon now holds 1,070,329 shares, worth roughly $141.2 million.
Mizuho downgraded its Intra-Cellular Therapies Inc [ITCI] rating to a Neutral from a an Outperform in a research note published on February 24, 2025; the price target was decreased to $132 from $140. A number of analysts have revised their coverage, including Canaccord Genuity’s analysts, who decreased its forecast for the stock in late January from “a Buy” to “a Hold”. Piper Sandler also remained covering ITCI and has increased its forecast on September 06, 2024 with a “an Overweight” recommendation from previously “Neutral” rating. Robert W. Baird started covering the stock on January 03, 2024. It rated ITCI as “an Outperform”.
Price Performance Review of ITCI
On Monday, Intra-Cellular Therapies Inc [NASDAQ:ITCI] saw its stock jump 0.08% to $131.92. Over the last five days, the stock has gained 0.17%. Intra-Cellular Therapies Inc shares have risen nearly 57.95% since the year began. Nevertheless, the stocks have risen 89.21% over the past one year. While a 52-week high of $131.87 was reached on 03/31/25, a 52-week low of $64.09 was recorded on 01/07/25. SMA at 50 days reached $129.20, while 200 days put it at $92.03.
Levels Of Support And Resistance For ITCI Stock
The 24-hour chart illustrates a support level at 131.83, which if violated will result in even more drops to 131.74. On the upside, there is a resistance level at 131.98. A further resistance level may holdings at 132.04. The Relative Strength Index (RSI) on the 14-day chart is 86.14, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.25, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 3.95%. Stochastics %K at 93.52% indicates the stock is a selling.
How much short interest is there in Intra-Cellular Therapies Inc?
A steep rise in short interest was recorded in Intra-Cellular Therapies Inc stocks on 2025-03-14, growing by 0.36 million shares to a total of 2.67 million shares. Yahoo Finance data shows the prior-month short interest on 2025-02-14 was 2.31 million shares. There was a rise of 13.5%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 11, 2023 when TD Cowen began covering the stock and recommended ‘”an Outperform”‘ rating along with a $75 price target.
